Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | ACP3 | P15309 | 2/20 | 0.46 |
| ▸ | PGK1 | P00558 | 4/20 | 0.45 |
| ▸ | PGK2 | P07205 | 4/20 | 0.45 |
| ▸ | DAO | P14920 | 1/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.40 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | MMP2 | P08253 | 1/20 | 0.40 |
| ▸ | KDM1A | O60341 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9102020 | 0.78 | ACP3 (0.54) | ACP3PGK1PGK2ALDH1A1 | |
| SCHEMBL14769151 | 0.77 | PGK1 (0.47) | PGK1PGK2DAOCA12MMP2 | |
| SCHEMBL30836028 | 0.76 | KMT2A (0.43) | KMT2ADAOKDM1AMAOAMAOB | |
| SCHEMBL17021449 | 0.76 | KMT2A (0.43) | KMT2ADAOKDM1AMAOAMAOB | |
| SCHEMBL5262966 | 0.76 | KMT2A (0.52) | KMT2ADAOPTGS1KDM1AMAOA | |
| SCHEMBL472531 | 0.76 | KMT2A (0.52) | KMT2ADAOPTGS1KDM1AMAOA | |
| SCHEMBL11951542 | 0.75 | KMT2A (0.50) | KMT2ADAOKDM1AMAOAMAOB | |
| SCHEMBL14769117 | 0.74 | PGK1 (0.48) | PGK1PGK2 | |
| Hydrochloric Acid SCHEMBL3565805 | 0.74 | KMT2A (0.50) | KMT2ADAOPTGS1KDM1AMAOA | |
| SCHEMBL19555418 | 0.74 | KMT2A (0.54) | KMT2ADAOPTGS1KDM1AMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024059317-A1 | YAP/TAZ-TEAD ONCOPROTEINS INHIBITORS | BRIDGENE BIOSCIENCES, INC. (US) | 2024-03-21 | — | — | WO | disclosed |
| EP-3107898-B1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICALS CO (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2020-06-23 | — | — | US | disclosed |
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-04 | — | — | US | disclosed |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-07-03 | — | — | US | disclosed |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-03-09 | — | — | US | disclosed |
| EP-3107898-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | Takeda Pharmaceutical Company Limited (JP) | 2016-12-28 | — | — | EP | disclosed |
| US-9156829-B2 | Cycloalkyl and heterocycloalkyl compounds as orexin receptor antagonists | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-10-13 | — | — | US | disclosed |
| WO-2015124932-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | TAKEDA CAMBRIDGE LIMITED (GB) | 2015-08-27 | — | — | WO | disclosed |
| US-20150232460-A1 | NOVEL COMPOUNDS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2015-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180282309-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | KMT2A 1255/4885ACP3 4565/4885PGK1 4486/4885 |
| US-10011588-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | KMT2A 1264/4885ACP3 4609/4885PGK1 4482/4885 |
| US-20170066744-A1 | 1,2-SUBSTITUTED CYCLOPENTANES AS OREXIN RECEPTOR ANTAGONISTS | HCRTR1, HCRTR2, NPY1R | KMT2A 1264/4885ACP3 4609/4885PGK1 4482/4885 |
| US-10689373-B2 | 1,2-substituted cyclopentanes as orexin receptor antagonists | HCRTR1, HCRTR2, NPY1R | KMT2A 1255/4885ACP3 4565/4885PGK1 4486/4885 |
| US-20150232460-A1 | NOVEL COMPOUNDS | CNKSR1, RDX, RB1 | KMT2A 3548/4885ACP3 1620/4885PGK1 4567/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.